The aim of this study was to evaluate the non chemotactic function of CCL18 on human dendritic cells (DCs). In different protocols of DC differentiation, CCL18 was highly produced suggesting that it may constitute a mandatory mediator of the differentiation process. Differentiation of monocytes from healthy subjects in the presence of GM-SCF and CCL18 led to the development of DCs with a semi-mature phenotype, with intermediate levels of costimulatory and MHC class II molecules, increased CCR7 expression, which induced in coculture with allogenic naive T cells, an increase in IL-10 production. The generated T cells were able to suppress the proliferation of effector CD4 +
Abstract
The aim of this study was to evaluate the non chemotactic function of CCL18 on human dendritic cells (DCs). In different protocols of DC differentiation, CCL18 was highly produced suggesting that it may constitute a mandatory mediator of the differentiation process. Differentiation of monocytes from healthy subjects in the presence of GM-SCF and CCL18 led to the development of DCs with a semi-mature phenotype, with intermediate levels of costimulatory and MHC class II molecules, increased CCR7 expression, which induced in coculture with allogenic naive T cells, an increase in IL-10 production. The generated T cells were able to suppress the proliferation of effector CD4 +
CD25
-cells, through a cytokine dependent mechanism, and exhibited characteristics of type 1 T regulatory cells.
The generation of tolerogenic DCs by CCL18 was dependent upon the production of indoleamine 2,3-dioxigenase through an IL-10 mediated mechanism. Surprisingly, when DCs originated from allergic patients, the tolerogenic effect of CCL18 was lost in relation with a decreased binding of CCL18 to its putative receptor. This study is the first to define a chemokine able to generate tolerogenic DCs. However, this function was absent in allergic donors, and may participate to the decreased tolerance observed in allergic diseases.
Introduction
Chemokines are a large family of related molecules classified on the basis of structural properties, according to the number and position of conserved cysteine residues, with two major (CXC and CC) and two minor (C and CX3C) chemokine subfamilies. They act through seven-transmembrane domain G protein-coupled receptors on their target cells 1, 2 . These small and secreted proteins are mainly involved in leukocyte chemoattraction and cytokine-like activities, including regulation of angiogenesis, fibrosis, proliferation, and apoptosis 1 , but have also other immune functions including T cell activation 3 and differentiation 4 . Some chemokines have been shown to directly regulate the ability of dendritic cells (DCs) to prime a Th1 cell response by modifying their maturation and/or cytokine production [5] [6] [7] . DCs are key players in activation of the adaptive immune system by their capacity of antigen presentation to and priming of T cells. DCs serve as sentinels, recognizing antigens, and upon maturation migrate to the draining lymph nodes to initiate the effector primary immune response.
Moreover, an increasing body of evidence suggests that beside their immunogenic role in inflammatory conditions, DCs may also play a role in induction of tolerance, in particular in steady-state conditions, predominantly by inducing regulatory T cells 8 
(Treg).
CCL 18 is a chemokine expressed at high levels in lung and lymph nodes, mainly produced by antigen presenting cells such as monocytes, macrophages and immature DCs 9, 10 . CCL18
was first identified as a chemotactic factor for naïve CD4 + T cells 11 and immature DCs 10 suggesting a main role in primary immune responses, however, it can also attract, skinhoming memory T cells 12 , Th2 cells and basophils 13 , suggesting a role also in secondary immune responses. CCL18 is mainly induced by the Th2 type cytokines IL-4 and IL-13, and inhibited by IFN-γ 9 . Accordingly, an overexpression of this chemokine has been identified in allergic diseases such as asthma and atopic dermatitis 12, 13 . In contrast CCL18 is able to inhibit CCR3-dependent chemoattraction of eosinophils by eotaxin 14 , is induced by the suppressive
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From cytokine IL-10, and we recently showed that it could generate adaptive regulatory T cells 15 suggesting that CCL18 may also play an antagonist role in allergic diseases. CCL18 is also dysregulated in a number of other diseases without preferential Th2 polarization, such as leukemia and Gaucher disease 16, 17 . It is of interest to point out that CCL18 gene is thought to be absent in rodents 18 , and is still an orphan chemokine without known receptor, precluding experimental studies to assess its functionality in vivo.
Because DCs appear as major targets and producers of CCL18, the purpose of this study was to assess the direct immune effect of CCL18 on human DC differentiation, maturation and polarization of T cell immune responses according to the atopic status of the donors. This study shows for the first time, to our knowledge, that a chemokine can differentiate DCs in tolerogenic cells able to prime regulatory T cells. This effect of CCL18 was mediated through the induction of IL-10 and IDO by DCs obtained from healthy subjects, and suggests that the constitutive expression of CCL18 in the lung may play a tolerogenic role in steady-state conditions. However, in allergic patients, this property was lost, in association with a decreased binding of CCL18 to its putative receptor.
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Materials and Methods

Subjects
Venous blood was obtained from 33 healthy non allergic (NA) subjects, with no history of allergic diseases, exhibiting total IgE levels < 100 KU/L and absence of allergen-specific IgE antibodies. Venous blood was also collected from 15 allergic (A) patients. These patients exhibited a history of allergic rhinitis and/or intermittent asthma, positive skin prick tests to common aeroallergens, positive allergen specific IgE antibodies (more than 3 KU/L), and elevated total IgE levels. None had received oral or inhaled corticosteroids within 2 months before sample collection. Patients were under β2 agonists as needed. The study was approved by the Comité consultatif de protection des personnes dans la recherche biomédicale de Lille (CP 04/45). All donors signed an informed consent form in accordance with the Declaration of Helsinki.
Generation of dendritic cells
Peripheral blood mononuclear cells (PBMCs) were isolated via density gradient centrifugation using Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden).
CD14
+ monocytes were isolated by magnetic column purification on the basis of positive selection with anti-CD14 microbeads (Miltenyi Biotech, Auburn, CA) with a purity of 96% and used to generate DC by culturing 1x10 6 CD14 + cells in RPMI-1640 medium with 2mmol/mL glutamine, 100µg/mL ticarpen, and 10% Fetal Calf Serum (FCS) (complete RPMI) supplemented with various cytokine cocktails for 6 days according to protocols previously described in the literature [19] [20] [21] [22] [23] . In 5 of these protocols, GM-CSF at 25ng/mL was associated with one of the following cytokine, IL-4 (10ng/mL), IL-13, TGF-β1, IL-15, IFN-α and IL-3 all at 5ng/mL. In the last one, IFN-α was associated with IL-3, both at 5ng/mL. In
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From some experiments neutralizing anti-CCL18 antibody (R&D Systems, Minneapolis, MN, USA) was added to the culture at day 0, 2 and 4 at a concentration of 10μg/mL. Blocking activity of the CCL18 antibody was evaluated by its ability to inhibit CCL18-induced naïve T cell chemotaxis, which was around 45% (data not shown). Three protocols were thereafter routinely used, one as negative control with GM-CSF alone at 25ng/mL ( GM DCs), the classical protocol of DC generation with GM-CSF and IL-4 ( GM/IL-4 DCs) and one consisting in the addition of 10 -7 M CCL18 to GM-CSF ( GM/CCL18 DCs) (R&D Systems). Preliminary dose response experiments showed that the optimal CCL18 concentration was 10 
Flow cytometry sorting of T cell subsets
Phenotype analysis
DC phenotype was evaluated by flow cytometry using a standardized protocol as previously As a control we used a small molecular weight protein derived from Plasmodium falciparum, as previously described 15 .
Suppression assays
A fixed number of purified flow cytometry sorted CD4 
Statistical analysis
Statistical analysis for production of cytokines was first performed within the subgroups by using the ANOVA test and, when significant, followed by the post Dunnett's Multiple
Comparison Test. The paired t test was performed for phenotype analysis and suppression assays. P values of less than 0.05 were regarded as statistically significant. Statistical analysis was performed using the software Graphpad prism (GraphPad Software, La Jolla, USA).
Results
CCL18 production increases during DC differentiation and is higher in DCs from
allergic than healthy subjects.
CCL18 has been shown to be produced by immature DCs at high levels in standard protocols of differentiation associating GM-CSF and Th2 cytokines 10 . We first examined the kinetics of production of CCL18 in GM+IL-4 differentiated DCs in non allergic versus allergic subjects.
As shown in Figure 1A , DCs from allergic donors produced more CCL18 than healthy subjects in both their immature and mature stages. The increase in CCL18 production also occurred when the cells were washed every two days showing that it was not related to over time accumulation (data not shown). Intrinsic CCL18 production correlated with the appearance of the DC differentiation markers HLA-DR and CD80 and the loss of the monocyte marker CD14 ( Figure 1A ). In order to evaluate the effect of CCL18 on DC maturation, and since immature DCs produce CCL18 which may have an autocrine effect, we used a neutralizing antibody against CCL18, during differentiation of DCs obtained from healthy subjects by the conventional IL-4+GM-CSF protocol. Despite high doses and repetitive administration of the antibody, the production of CCL18 by GM/IL-4 DCs was only neutralized by 45% as assessed by ELISA (data not shown). The partial neutralization of CCL18 by a blocking antibody, did not modify the DC surface phenotype (data not shown), increased the DC production of proinflammatory cytokines IL-6, but not of IL-23 and IL-10, and led in DC/T cell cocultures to a decrease in IL-10 and an increase in IL-4 productions in non allergic donors, whereas no modifications were observed in allergic donors ( Figure 1B ).
We therefore decided to evaluate other protocols of differentiation described in the literature in order to determine a protocol which would not induce the production of CCL18
.
Surprisingly, all protocols tested generated the production of CCL18 at high levels, even those not using CCL18 inducing Th2 cytokines ( Figure 1C ). When monocytes were differentiated with GM-CSF alone, a very small production of CCL18 was observed ( Figure 1C ).
Furthermore, when the atopic status was taken into account, DCs from allergic patients secreted more CCL18 than non allergic subjects in all DC differentiation protocols but especially in those using Th2 cytokines (10 fold increase for IL-13 and IL-4 respectively and 5 fold for the others) ( Figure 1C ). The constant secretion of CCL18 in all protocols let us suppose that this chemokine may be an obligatory mediator involved in DC differentiation.
To test this hypothesis we evaluated a protocol combining CCL18 and GM-CSF ( GM/CCL18 DCs), and compared it with GM-CSF alone as negative control ( GM DCs), and the standard GM-CSF + IL-4 as positive control ( GM/IL-4 DCs). It is of note that monocytes treated without growth factor or with CCL18 alone died very rapidly after a few days of culture.
GM/CCL18 DCs from healthy subjects have characteristics of semi-mature DCs and produce IL-10.
GM/CCL18 DCs were generated from monocytes obtained from healthy subjects. The microscopic morphology of the generated DCs was assessed. After maturation, GM/IL-4 DCs exhibited typical DC morphology, with large cell bodies and sharp cytoplasmic projections, did not adhere to plastic and promoted few cluster formations. GM/CCL18 DCs were bigger with spread cytoplasmic projections and more adherent than GM/IL-4 DCs, and aggregated in clusters.
GM-CSF DCs were also big and granular but with fewer cytoplasmic projections than GM/IL-4 DCs (data not shown). The cell surface phenotype was then evaluated by flow cytometry. (Table 1) . Surprisingly, when GM/CCL18 DCs were generated from allergic subjects, they exhibited characteristics similar to the negative control GM DCs (Table 1 and Figure 2 ). To further assess the differences between the generated DCs, cytokines were assayed in the mature DC supernatants. IL-10 and TGF-β were assessed as anti inflammatory cytokines and IL-12, IL-6 and IL-23 as pro-inflammatory cytokines. GM/CCL18 DCs produced enhanced amounts of IL-10, as compared with GM/IL-4 DCs and GM DCs ( Figure 3A) . The other regulatory cytokine TGF-β was also slightly increased but the difference did not reach statistical significance. All the other cytokines were not significantly modified ( Figure 3A ) or were absent, such as for IL-12 (data not shown).
Similarly to the observations for the cell surface phenotype, GM/CCL18 DCs obtained from allergic donors did not show differences with GM DCs ( Figure 3A ) and exhibited less IL-10 and IL-6 production than GM/CCL18 DCs obtained from non allergic subjects. The effect of addition of exogenous CCL18 to GM/IL-4 DCs from non allergic subjects was evaluated on IL-10 production. As shown in figure 3B , IL-10 production was two fold higher than for GM/IL-4 DCs but one third lower than for GM/CCL18 DCs. Altogether these data suggest that in healthy subjects CCL18 induces IL-10-producing DCs, described to be tolerogenic, whereas in allergic patients these DCs seemed unable to respond to CCL18.
For GM/CCL18 DC-(18.9 ± 2 %) and GM/IL-4 DC-(25.6 ± 2 %) primed T cells (Fig 4C) .
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The above data suggest that DCs from healthy subjects differentiated in the presence of CCL18 favor the generation of T cells over-expressing the anti-inflammatory cytokine IL-10, but not Foxp3. contrast to healthy subjects, GM/CCL18 DCs generated from allergic patients did not suppress, but enhanced effector T cell proliferation ( Figure 5A ). Regulatory T cells have been shown to act through two main mechanisms, production of suppressive cytokines such as IL-10 and TGF-β and through cell contact inhibition. To determine the mechanism involved in the suppressive effect of T cells primed by GM/CCL18 DCs generated from healthy subjects, inhibition of IL-10 and TGF-β1 and experiments using cell supernatants were performed.
CD4
Blocking anti-IL-10 and anti-TGF-β1 antibodies were added to the proliferation assays to 
CCL18 generates tolerogenic DCs in healthy donors through IL-10-induced Indoleamine 2,3-dioxigenase (IDO) production
Next, the mechanism whereby CCL18 was inducing tolerogenic DCs in healthy subjects was evaluated. Dysregulation of the tryptophan metabolism in DCs has been shown to generate regulatory T cells, in particular through the production of the tryptophan catabolizing enzyme indoleamine-pyrrole 2,3 dioxygenase 25 (IDO). Therefore, the production of IDO was assessed in the supernatants of mature differentiated DCs from healthy donors. Increased levels of IDO were detected in supernatants of GM/CCL18 DCs as compared with the other protocols of DC differentiation ( Figure 6A ). As IL-10 has been described as an inducer of IDO 25, 26 , the effect of IL-10 inhibition during differentiation of DCs was examined using a neutralizing IL-10
antibody. As compared with isotype treated DCs, anti-IL-10 treated GM/CCL18 DCs exhibited a statistically significant decrease of IDO production, whereas GM DC and GM/IL-4 DC IDO levels
were not affected ( Figure 6B ). To evaluate if anti-IL-10 treated GM/CCL18 DCs were impaired in their ability to generate Treg cells, they were cocultured for 5 days with naïve T cells and their cytokine secretion determined. As shown in Figure 6C , there was a strong reduction in the production of IL-10 and IFN-γ, whereas IL-4 production remained elevated. Altogether,
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CCL18 does not bind to DCs from allergic patients
For all examined parameters, the results observed with GM/CCL18 DCs obtained from allergic subjects were similar to those obtained with GM DCs, suggesting that CCL18 could not act on its putative receptor in these patients. Although CCL18 receptor is still unknown, its presence can be visualized using its labeled ligand. Therefore, its expression was examined by flow cytometry using biotinylated CCL18. The results showed that all differentiated DCs from allergic subjects bound less CCL18 than healthy subjects as shown by decreased MFI and % of expression after subtraction of the biotinylated control protein ( Figure 7A and 7B) . Taken together, these data suggest that in allergic subjects, decreased CCL18R binding on DCs may explain the absence of tolerogenic effect of CCL18.
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Discussion
In this study, we evaluated the immune non chemotactic function of CCL18 on DCs. CCL18 endogenous production was much higher in DCs obtained from allergic than non allergic subjects, in particular for the protocols using IL-4 and IL-13 as differentiating cytokines. This might be linked to a priming effect already present in vivo, related to the Th2 cytokines present in allergic patients, which are known to induce CCL18 9 . Alternatively, this may also be related to an intrinsic capacity of DCs from allergic patients to produce more CCL18 than non allergic donors. This latter hypothesis is supported by the elevated level of CCL18 that persisted in the maturation phase at day 8 in supernatants from allergic subjects, even after DC extensive washing and removal of Th2 cytokines. It is also consistent with the ability of DCs obtained from allergic subjects to behave differently from those obtained from non allergic subjects. For example, we and others have previously shown that DCs from allergic patients are able to favour a Th2 profile when cocultured with naive T lymphocytes versus a Th1 profile for non allergic subjects [27] [28] [29] . In our initial experiments, the inhibition of half of the endogenous CCL18 production during the differentiation process did lead to an increase in the ratio of pro-versus anti-inflammatory cytokines in DCs, and to a decrease in IL-10 production in DC/T cell cocultures. However, this endogenous production of CCL18 by DCs from healthy subjects was not enough to induce a regulatory phenotype in T cells as shown by the absence of inhibition of effector T cell proliferation by GM/IL-4 DCs. We also performed dose response experiments, which showed that the minimal exogenous CCL18 concentration required to obtain a tolerogenic effect on DCs was 10 -8 M, i.e., 80ng/ml, therefore 5 fold more than the quantity produced by DCs from healthy subjects. Such high environmental concentrations may be achieved in the lung, where CCL18 is constitutively expressed. It has been previously shown that alveolar macrophages produce high levels of CCL18 9, 13 , five millions alveolar macrophages being enough to attain at baseline the 10 -8
M concentration. In
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the present study, exogenous CCL18 was found to drive DCs with characteristics of semimature DCs only in non allergic subjects. Indeed, their GM/CCL18 DCs still expressed macrophage lineage markers, such as CD14, CD16 and the macrophage mannose receptor CD206, but also exhibited a partial maturation with intermediate levels of costimulatory and MHC class II molecules, and a decreased production of the pro inflammatory cytokine IL23p40. Semi-mature DCs have been previously shown to develop in response to different environmental stimuli such as IL-6 30 , TNF-α 31,32 vitamin D3 and dexamethasone 33, 34 . The generation of semi-mature DCs by CCL18 was not related to an overproduction of IL-6 as shown in DC supernatants, and although TNF-α was used in DC maturation phase in all protocols, only the CCL18 protocol led to a semi-mature phenotype. It is of interest that it has been previously shown that semi-mature DCs induced by vitamin D3 strongly promotes CCL18 secretion 10 . Different surface phenotypes have been identified among semi-mature DCs, including increased expression of inhibitory costimulatory molecules such as PD-L1 or ICOS-L [34] [35] [36] . In the present study, CCL18 primed DCs did not show increased expression of these inhibitory molecules, suggesting that they were not involved in the observed tolerogenic effect. Interestingly, CCL18 primed DCs expressed high levels of CCR7, a chemokine receptor necessary to enter secondary lymphoid tissues. In vivo, it has been reported that CCR7 expression by semi-mature DCs is critical to tolerance induction in steady-state conditions, by allowing these cells to immigrate into lymph nodes where they interact with specific T cells 37 . It has been recently shown that antigen transport by CCR7-dependent migrating lung-derived DCs to the draining bronchial lymph nodes was a necessary requirement for successful induction of tolerance towards innocuous inhaled antigens and for protection against the development of allergic airway diseases 38 . As CCL18 is constitutively expressed in the lung, these data and our results suggest that in healthy subjects, in steadystate conditions, CCL18 may constitute a novel priming mechanism of semi-mature lung DCs
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From able to migrate to lymph nodes and to participate to the maintenance of tolerance against inhaled antigens including allergens. Semi-mature DCs are known to produce increased quantities of IL-10, a cytokine able to alter DC maturation process. Exposure of immature DCs to IL-10 results in a reduced expression of costimulatory and MHC class II molecules and production of proinflammatory cytokines 39 , and leads to the development of adaptive regulatory T cells, including Tr1 cells 40, 41 , whereas fully mature DCs are resistant to IL-10 effects 42 . In our study, the induction of IL-10 by DC differentiated in the presence of CCL18
led to Treg cells that had the features of Tr1 cells, since they did not overexpress Foxp3, exhibited low levels of IL-4, and intermediate levels of IFN-γ, and acted through a soluble cytokine dependent mechanism, as originally described for Tr1 cells 40, [43] [44] [45] . A high level of IL-10 was detected in DC/T cell co-cultures, which was higher than the level produced by DCs alone, with 10 fold more IL-10 -producing lymphocytes than DCs, showing that the production of IL-10 in the co-cultures was also derived from T cells. Until recently, the mechanisms involved in IL-10-induced Tr1 induction remained elusive, however, a recent study showed that induction of Tr1 cells by IL-10 primed DCs was IL-10-dependent and required the ILT4/HLA-G signaling pathway 46 . We now provide here a new mechanism of Tr1 differentiation, involving activation of DCs through the CCL18 pathway. IL-10 appeared as the main mediator responsible for the generation of Tregs in healthy subjects. Indeed, its inhibition during the differentiation of DCs in the presence of CCL18, changed the T cell coculture cytokine profile from an anti-inflammatory to a pro-inflammatory profile, through the inhibition of IDO. We have previously shown that CCL18 was also able to convert effector memory CD4 + CD25 -T cells into adaptive regulatory T cells, through a TGF-β-dependent mechanism 15 . Although GM/CCL18 DC primed regulatory T cells did also exert their suppressive function partly through TGF-β, the initial mechanism of DC priming did not seem related to TGF-β as shown by the absence of difference in TGF-β production among the therefore, CCL18 may be added to the arsenal of therapeutic tools devoted to induce tolerance. However, in allergic subjects, no change was observed in surface markers, cytokine profiles and function of DCs which was consistent with the decreased CCL18R staining on DC cell surface. Although the precise nature of CCL18R is still unknown, decreased binding of CCL18 to its putative receptor may be related to a desensitization phenomenon linked to the elevated endogenous levels of CCL18 found in DC supernatants from allergic subjects as compared with control subjects. However, albeit we treated DCs from healthy subjects with twice the endogenous concentration of CCL18 found in DCs from allergic patients, CCL18R
was still expressed on DCs from healthy subjects, suggesting that another mechanism might take place. Accordingly, no differences were observed between the different differentiation protocols in G protein-coupled receptor kinase 2 and β -arrestin expression, two molecules controlling chemokine desensitization (data not shown). The exact mechanisms regulating CCL18R expression in allergic subjects need further investigation. However, these data suggest that the absence of feedback regulation by CCL18R in allergic subjects may participate to the lack of resolution of allergic inflammatory reactions.
In conclusion this study shows for the first time that CCL18 can generate functional tolerogenic DCs able to prime regulatory T cells in healthy subjects, suggesting that CCL18 may play a potent role in inducing and maintaining tolerance to inhaled antigens through its constitutive lung expression and priming of semi-mature DCs. In allergic subjects, this effect was lost, and may account for sustained allergic inflammation in these patients.
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